+

WO2009091372A1 - Timbre transdermique de médicament actif - Google Patents

Timbre transdermique de médicament actif Download PDF

Info

Publication number
WO2009091372A1
WO2009091372A1 PCT/US2008/009452 US2008009452W WO2009091372A1 WO 2009091372 A1 WO2009091372 A1 WO 2009091372A1 US 2008009452 W US2008009452 W US 2008009452W WO 2009091372 A1 WO2009091372 A1 WO 2009091372A1
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
substrate
circuit board
patch
recited
Prior art date
Application number
PCT/US2008/009452
Other languages
English (en)
Inventor
Jamal S. Yanaki
Original Assignee
Actuvatek, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/009,409 external-priority patent/US20080214985A1/en
Priority claimed from US12/009,443 external-priority patent/US8862223B2/en
Application filed by Actuvatek, Inc. filed Critical Actuvatek, Inc.
Publication of WO2009091372A1 publication Critical patent/WO2009091372A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Definitions

  • the invention disclosed herein relates to the transdermal administration of medicaments to human and animal subjects. More particularly, the present invention pertains to active iontophoretic delivery systems in which electrical contacts are applied to the surface of the skin of a subject for the purpose of delivering medicament through the surface of the skin into underlying tissue.
  • the direct current employed in active iontophoresis systems may be obtained from a variety of electrical power sources. These include consumable and rechargeable batteries, paired regions of contrasting galvanic materials that when coupled by a fluid medium produce minute electrical currents, and electrical equipment that ultimately receives power from a wall socket. The later in particular are of such bulk, weight, and cost as to necessitate being configured as items of equipment distinct from the electrical contacts that are applied directly to the skin in administering a medicament iontophoretically. Accordingly, such power sources limit the mobility of the patient during the time that treatment is in progress.
  • a flow of electrical current requires an uninterrupted, electrically-conductive pathway from the positive pole of a power source to the other, negative pole thereof.
  • Living tissue is made up primarily of fluid and is, therefore, a conductor of electrical current.
  • the opposite poles of a power source are electrically coupled to respective, separated contact locations on the skin of the subject. The difference in electrical potential created by the power source between those contact locations causes a movement of electrons and electrically charged molecules, or ions, through the tissue between the contact locations.
  • the polarity of the net overall electrical charge on dissolved molecules of a medicament determines the nature of the electrical interconnection that must be effected between the power source that is used to drive the system and the supply of medicament that is positioned on the skin of the patient at one of the contact locations to be used by the system.
  • a positively charged medicament in a reservoir against the skin of a patient is coupled to the positive pole of the power source that is to be used to administer the medicament iontophoretically.
  • a reservoir on the skin of a patient containing a negatively charged medicament must be coupled to the negative pole of such a power source. Examples of common iontophoretically administrable medicaments in each category of polarity are listed in the table below.
  • the medicament is housed in a fluid reservoir, or medicament, which is then positioned electrically conductively engaging the skin of the subject at an anatomical location overlying the tissue to which the medicament is to be administered.
  • the medicament matrix can take the form of a gel suspension of the medicament or of a pad of an absorbent material, such as gauze or cotton, which is saturated with fluid containing the medicament.
  • the fluid containing the medicament is provided from the manufacturer in the absorbent pad. More commonly, the fluid is added to the absorbent pad by a medical practitioner at the time that the medicament is about to be administered to a subject.
  • An iontophoretic circuit for driving the medicament through the unbroken skin is established by coupling the appropriate pole of the power source through the medicament matrix to the skin of the subject at the anatomical location at which the medicament is to be administered. Simultaneously, the other pole of the power source is coupled to an anatomical location on the skin of the subject that is distanced from the medicament matrix.
  • the coupling of each pole of the power source is effected by the electrical connection of each pole to a respective electrode.
  • the electrode at the medicament matrix is referred to as an active electrode; the electrode at the contact location on the skin distanced from the medicament matrix is referred to as a return electrode.
  • the medicament matrix with an associated active electrode may be conveniently retained against the skin by a first adhesive patch, while the return electrode may be retained against the skin at some distance from the medicament matrix using a distinct second adhesive patch.
  • the medicament matrix with the associated active electrode, as well as the return electrode may be carried on a single adhesive patch at, respective, electrically isolated locations.
  • iontophoresis to administer medicaments to a subject is advantageous in several respects.
  • Medications delivered by an active iontophoretic system bypass the digestive system. This reduces digestive tract irritation.
  • medicaments administered orally are less potent than if administered transcutaneously. In compensation, it is often necessary in achieving a target effective dosage level to administer orally larger quantities of medicament than would be administered transcutaneously.
  • Active iontophoretic systems do not require intensive skin site sanitation to avoid infections. Patches and the other equipment used in active iontophoresis do not interact with bodily fluids and, accordingly, need not be disposed as hazardous biological materials following use. Being a noninvasive procedure, the administration of medicament using an active iontophoretic system does not cause tissue injury of the types observed with hypodermic injections and with intravenous catheterizations. Repeated needle punctures in a single anatomical region, or long term catheter residence, can adversely affect the health of surrounding tissue. Needle punctures and catheter implantations inherently involve the experience of some degree of pain. These unintended consequences of invasive transcutaneous medicament administration are particularly undesirable in an area of the body that, being already injured, is to be treated directly for that injury with a medicament. Such might be the case, for example, in the treatment of a strained muscle or tendon.
  • the dosage of a medicament delivered iontophoretically is conveniently and accurately measured by monitoring the amount and the duration of the current flowing during the administration. With current being measured in amperes and time being measured in minutes, the dosage of medicament given transcutaneously is given in units of ampere-minutes. Due to the minute quantities of medicament required in active iontophoresis, medicament dosage in active iontophoresis is generally prescribed in milliamp-minutes. Dosage measured in this manner is more precise than is dosage measured as a' fluid volume or as a numbers of tablets.
  • the present invention promotes the wide use of active iontophoretic systems by providing improved components and combinations of components for active iontophoretic systems.
  • the present invention thus improves the safety of patients and reduces the technical difficulty of related tasks that must by performed by medical personnel.
  • teachings of the present invention enhance the reliability and the user friendliness of active iontophoretic systems and lead to reductions in the costs associated with the manufacture of such systems, as well as with the use of such systems to deliver medication.
  • a fully-integrated, independently accurately performing adhesive active transdermal medicament patch is provided.
  • the present invention contemplates related methods of design and manufacture, as well as methods pertaining to the treatment of patient health problems.
  • Figure 1 is a perspective view of an embodiment of a fully-integrated, active transdermal medicament patch incorporating teachings of the present invention being worn during activity by a patient requiring the localized administration of a medicament;
  • Figure 2 A is a perspective view of the active transdermal medicament patch of Figure 1 showing the substrate of the patch, a moistened medicament matrix mounted on the therapeutic face of the substrate that engages the skin of the patient in Figure 1 , and a release liner in the process of being peeled from an adhesive coating on the portion of the therapeutic face not occupied by the medicament matrix;
  • Figure 2B is a perspective view of the active transdermal medicament patch of Figure 2A with the release liner illustrated in Figure 2A fully removed;
  • Figure 2C is a partially-exploded perspective view of the active transdermal medicament patch of Figure 2B that reveals the entirety of the therapeutic face of the substrate of the medicament patch;
  • Figure 3 A is a perspective view of the active transdermal medicament patch of Figure 1 taken from the side thereof visible in Figure 1, the side opposite that illustrated in Figures 2A-2C;
  • Figure 3 B is an exploded perspective view of the active transdermal medicament patch of Figure 3 A showing the cover of the medicament patch, the upper face of the substrate of the medicament patch, and a circuit board sandwiched therebetween in a folded, compact state;
  • Figure 3C is a perspective view of the circuit board of Figure 3B in a partially- unfolded state thereof;
  • Figure 3D is a partially-exploded perspective view of the circuit board of Figure 3 C in a fully-unfolded, planar state thereof;
  • Figure 4 is a cross-sectional elevation view of the active transdermal medicament patch of Figure 2 A taken along section line 4-4 shown therein;
  • Figure 5 A is cross-sectional elevation view of the active transdermal medicament patch of Figure 4 inverted and disposed against the skin of a patient, thereby to illustrate the movement of a medicament of positive polarity through subcutaneous tissue of the patient;
  • Figure 5B is a diagram like that of Figure 5A, illustrating the movement of a medicament of negative polarity through subcutaneous tissue of a patient;
  • Figure 6 is a schematic diagram of an embodiment of electronics incorporating teachings of the present invention and suitable for use in the active transdermal medicament patch of Figure 5B;
  • Figures 7A and 7B are the same performance curve, but drawn in contrasting respective scales, of a first performance parameter of the electronics of Figure 6 taken over a predetermined therapy period;
  • Figures 8A and 8B are the same performance curve, but drawn in contrasting respective scales, of a second performance parameter of the electronics of Figure 6 taken over the same predetermined therapy period used in Figures 7 A and 7B;
  • Figure 9 is a performance curve of a third performance parameter of the electronics of Figure 6 taken over the same predetermined therapy period used in Figures 7A-7B and 8A-8B;
  • Figure 10 is a flowchart illustrating selected steps performed by the electronics of Figure 6.
  • connections between components illustrated in the figures are not limited to direct connections between those components. Rather, connections between such components may be modified, reformatted, or otherwise changed to include intermediary components without departing from the teachings of the present invention.
  • references in the specification to "one embodiment” or to “an embodiment” mean that a particular feature, structure, characteristic, or function described in connection with the embodiment being discussed is included in at least one embodiment of the present invention. Furthermore, the use of the phrase “in one embodiment” in various places throughout the specification is not necessarily a reference in each instance of use to any single embodiment of the present invention.
  • Figure 1 shows a patient 10 requiring the localized administration of a medicament to knee 12 thereof.
  • patient 10 is wearing on knee 12 thereof one embodiment of an active iontophoretic delivery system 14 that incorporates teachings of the present invention. While so doing, patient 10 is nonetheless able to . engage in vigorous physical activity, because delivery system 14 is entirely self- contained, and not supplied with power from any immobile or cumbersome power source.
  • Delivery system 14 takes the form of a fully-integrated, active transdermal medicament patch 16 that is removable adhered to the skin of knee 12 of patient 10 for the duration of a predetermined therapy period. The length of the therapy period during which medicament patch 16 must be worn is determined by the rate at which medicament patch 16 delivers medicament through the skin of patient 10 and the total dose of medicament that is to be administered.
  • FIGS 2A-4 taken together afford an understanding of the relationships existing among the structural elements of medicament patch 16.
  • Figures 2A-2C are views in various stages of disassembly of the side of medicament patch 16 that engages the skin of patient 10 in Figure 1.
  • Figures 3A-3D are similar views of the opposite side of medicament patch 16, the side thereof visible in Figure 1.
  • Figure 4 is a cross-sectional elevation view of medicament patch 16 taken along section line 4-4 in Figure 2A.
  • medicament patch 16 includes a flexible, planar electrically non-conductive biocompatible substrate 18 having a therapeutic face 20 on one side thereof that is intended to be disposed in contact with the skin of a patient, such as patient 10 in Figure 1.
  • Therapeutic face 20 is coated with a biocompatible adhesive to a sufficient extent as will enable therapeutic face 20 to be removably secured to the skin of patient 10.
  • the adhesive on therapeutic face 20 is shielded by a removable release liner 22.
  • release liner 22 is in the process of being peeled from therapeutic face 20. Release liner 22 has on the opposite sides thereof, respectively, first an exposed face 24 and second a contact face 26 that actually engages the adhesive on therapeutic face 20 of substrate 18.
  • medicament matrix aperture 28 Formed generally centrally through release liner 22 is a medicament matrix aperture 28.
  • medicament matrix aperture 28 is substantially filled by a generally planar medicament matrix 30 that exhibits a periphery 32 that closely conforms in shape and size to the shape and size of medicament matrix aperture 28.
  • Medicament matrix 30 can take the form of a gel suspension permeated by medicament, but as illustrated in Figure 2A, medicament matrix 30 is an absorbent pad of gauze or cotton that is saturated by a user with a fluid solution containing the medicament just prior to the use of medicament patch 16. In some instances, medicament patch 16 is supplied by the manufacturer with medicament solution already permeating medicament matrix 30.
  • the side of medicament matrix 30 visible in Figure 2A has a periphery 32 that encloses a skin contact surface 34 of medicament matrix 30.
  • Medicament matrix 30 projects through medicament matrix aperture 28 in such a manner that skin contact surface 34, while oriented generally parallel to the plane of release liner 22 and the plane of therapeutic face 20 of substrate 18, is separated from each by a distance that is approximately equal to the thickness T 30 of medicament matrix 30.
  • Skin contact surface 34 of medicament matrix 30 electrically conductively engage the skin of patient 10, when therapeutic face 20 of substrate 18 is disposed against and removably adhered thereto.
  • the embodiment of medicament matrix 30 shown in Figure 2A is an absorbent pad that must become permeated by a medicament solution before use.
  • the saturation of medicament matrix 30 with medicament solution 36 is a process intended to be performed by medical personnel just prior to the disposition of medicament patch 16 against the skin of a patient.
  • Figure 2A reveals that in such a process, drops of a medicament solution 36 may inadvertently be deposited on exposed face 24 of release liner 22 remote from medicament matrix 30. Also, at various locations about periphery 32 of medicament matrix 30, further drops of medicament solution 36 may be expected to overflow onto exposed face 24 of release liner 22 due to an over-saturation of portions of medicament matrix 30 with medicament solution 36. Such drops of medicament solution 36 do not, however, contact the adhesive on therapeutic face 20 of substrate 18. Instead, the drops of medicament solution 36 rest upon release liner 22 and are removed from medicament patch 16 with release liner 22, when release liner 22 is pealed from therapeutic face 20 of substrate 18 in the manner suggested by arrow S.
  • Figure 2B shows therapeutic face 20 of medicament patch 16 after the complete removal of release liner 22 therefrom.
  • therapeutic face 20 of medicament patch 16 has a periphery 38 and that medicament matrix 30 is positioned on therapeutic face 20 at one end of substrate 18 interior of periphery 38.
  • first electrode aperture 40 Formed through the opposite end of substrate 18 at a position separated from medicament matrix 30 is a first electrode aperture 40.
  • the size and shape of each of substrate 18, medicament matrix 30, and first electrode aperture 40 can vary from those depicted without departing from teachings of the present invention.
  • first electrode aperture 40 Accessible from therapeutic face 20 through first electrode aperture 40 is a planar first electrode, a return electrode 42 of medicament patch 16.
  • Return electrode 42 has a periphery 44 and, interior thereof on the side of return electrode 42 visible in Figure 2B, a skin contact surface 46. While possible to do so, return electrode 42 is not secured directly to therapeutic face 20 of substrate 18 in the manner of medicament matrix 30. Instead, return electrode 42 is maintained in a fixed relationship to other features of medicament patch 16 with the plane of skin contact surface 46 of return electrode 42 parallel to and closely coincident with the plane of therapeutic face 20. Consequently, a first electrode, such as return electrode 42, will routinely be characterized herein as being carried or positioned on therapeutic face 20, and thereby being located on the same side of substrate 18 as medicament matrix 30.
  • Return electrode 42 is separated from medicament matrix 30, and thus electrically isolated therefrom.
  • Skin contact surface 46 of return electrode 42 electrically conductive Iy engages the skin of patient 10, when therapeutic face 20 of substrate 16 is disposed against and removable adhered thereto. Accordingly, when medicament patch 16 is adhered to the skin of patient 10 as shown in Figure 1, return electrode 42 engages the skin of patient 10 at a location that is remote from the location engaged by medicament matrix 30.
  • FIG. 2C is a partially-exploded perspective view of medicament patch 16 of Figure 2B.
  • Medicament matrix 30 is depicted above and separated from therapeutic face 20 of substrate 18. Revealed thereby is a second electrode aperture 48 that is formed through substrate 18 at a position separated from first electrode aperture 40 and, correspondingly, also from return electrode 42.
  • Active electrode 50 Accessible from therapeutic face 20 through electrode aperture 44 is a planar second electrode, active electrode 50 of medicament patch 16.
  • Active electrode 50 includes an electrically-conductive planar backing layer 52 and a smaller electrically- conductive planar pH-control layer 54 disposed centrally thereupon. While possible to do so, active electrode 50 is not secured directly to therapeutic face 20 of substrate 18 in the manner of medicament matrix 30. Instead, by the attachment of active electrode 50 to other structural elements of medicament patch 16, active electrode 50 is maintained in a fixed relationship to other features of medicament patch 16 with the plane of each of backing layer 52 and pH-control layer 54 parallel to and closely coincident with the plane of therapeutic face 20. Consequently, a second electrode, such as active electrode 50, will routinely be characterized herein as being carried or positioned on therapeutic face 20, and thereby being located on the same side of substrate 18 as, for example, return electrode 42 and medicament matrix 30.
  • Figure 3 A is a perspective view of medicament patch 16 taken from the side thereof visible in Figure 1 when being worn by patient 10, the side of medicament patch 16 opposite that illustrated in Figures 2A-2C.
  • the side of medicament patch 16 shown in Figure 3A is encased in a protective cover 56 that is, but need not be, coextensive with substrate 18 of medicament patch 16.
  • cover 56 is depicted as being opaque and as including as the sole transparent portion thereof a small observation port 58. Consequently, features of medicament patch 16 beneath cover 56, such as first electrode aperture 40 and second electrode aperture 48, are shown in dashed lines.
  • FIG. 3 A Also included in dashed lines in Figure 3 A are some components of medicament patch 16 that are carried on substrate 18 beneath cover 56. These include electronic circuitry 60, a power source 62, and a switch 64. Switch 64 is depicted by way of example as a user-operated pull tab switch that permits the initiation of the operation of power source 62 by withdrawing an activation stem 66 of switch 64 from between cover 56 and substrate 18 in a manner suggested by arrow P.
  • Electronic circuitry 60 is surmounted by a light-emitting diode 67 or other visual indicator that communicates to a user information about the operative status of medicament patch 16. Light-emitting diode 67 is therefore located beneath and in alignment with observation port 58 in cover 56.
  • Electronic circuitry 60, power source 62, and switch 64 are not mounted directly to substrate 18, although any or all of these components of medicament patch 16 may be secured directly to substrate 18, or recessed in whole or in part into substrate 18. Instead, electronic circuitry 60, power source 62, and switch 64 are maintained in a fixed relationship to each other by being commonly secured to a circuit board 68. Circuit board 68 directly engages substrate 18 beneath cover 56, indirectly fixing each of electronic circuitry 60, power source 62, and switch 64 relative to each other and to other features of medicament patch 16.
  • Circuit board 68 will be explored in greater detail in Figures 3B-3D.
  • FIG 3B is an exploded perspective view of medicament patch 16 of Figure 3 A.
  • Cover 56 is depicted above and separated from substrate 18. Revealed thereby is an upper face 70 of substrate 18.
  • Upper face 70 has a periphery 72 that is substantially similar in size and shape to periphery 38 of therapeutic face 20 of substrate 18 shown in Figures 2B and 2C on the opposite side of substrate 18 from upper face 70.
  • First electrode aperture 40 and second electrode aperture 48 are formed through substrate 18 at spaced-apart locations. Visible through second electrode aperture 48 is medicament matrix 30 and a portion of a securement surface 74 thereof.
  • Medicament matrix 30 closes the side of second electrode aperture 48 that opens onto therapeutic face 20 of substrate 18. This is the situation when securement surface 74 of medicament matrix 30 engages therapeutic face 20 as shown in Figure 2B and as suggested in Figure 2C by the rendering in phantom on therapeutic face 20 of periphery 32 of medicament matrix 30.
  • circuit board 68 Sandwiched between cover 56 and upper face 70 of substrate 18 is circuit board 68. On the side of circuit board 68 visible in Figure 3B is a portion of a support face 76 thereof upon which are carried electronic circuitry 60, power source 62, and switch 64. These and other electrical circuit elements of medicament matrix 30 are electrically interconnected by an electrically-conductive printed circuit 78 that is applied to support face 76, usually before other electrical circuit elements are mounted on circuit board 68.
  • the depiction of printed circuit 78 in Figure 3B and thereafter herein is entirely schematic and is not intended to reveal any details about the layout particulars of printed circuit 78.
  • Power source 62 is, by way of example, a miniature battery of about 3 volts potential. The current supplied by power source 34 to electronic circuitry 60 is thus non- alternating. Power source 62 may be a battery of higher or lower output potential, or power source 62 may be a plurality of series-connected batteries of equal or unequal output potential. Accordingly, for most medical applications, the output voltage produced by power source 62 ranges from about 1.00 volt to about 15.00 volts. Alternatively, the output voltage produced by power source 62 ranges from about 2.00 volts to about 9.00 volts, or from about 3.00 volts to about 6.00 volts.
  • Support face 76 of circuit board 68 has a complex periphery 80 that assumes an irregular, asymmetrical barbell-shape. Alternative configurations in circuit board 68 would not depart from the teachings of the present invention.
  • periphery 80 of support face 76 is similar in shape, but smaller in extent than first electrode aperture 40.
  • periphery 80 of support face 76 is similar in shape, but smaller in extent than second electrode aperture 48.
  • Interconnecting first end 82 and second end 84 of circuit board 68 is an intermediate portion 86 of circuit board 68 in which periphery 80 of support face 76 is made up of linear segments.
  • Electronic circuitry 60 is mounted on support face 76 at first end 82 of circuit board 68.
  • Power source 62 and switch 64 are mounted on support face 74 of intermediate portion 86 of circuit board 68.
  • Support face 76 at first end 82 of circuit board 68 is shown as being free of electrical circuit elements, other than printed circuit 78. The positions of such electrical circuit elements of medicament patch 16 may be altered without departing from the teachings of the present invention.
  • intermediate portion 86 extends longitudinally along substrate 18 between first electrode aperture 40 and second electrode aperture 48 and laterally thereof to a linear portion 90 of periphery 72 of upper face 70 of substrate 18.
  • the phantom representation of intermediate portion 86 defines a circuit board contact area 88.
  • circuit board contact area 88 the side of circuit board 68 not visible in Figure 3B engages and may thus be secured, as with adhesive, to upper face 70 of substrate 18.
  • Circuit board 68 is manufactured from an electrically-nonconductive material. Depending on the absolute size of circuit board 68 and the relative size of circuit board 68 to the size of substrate 18, the material from which circuit board 68 is fabricated can be rigid or minimally flexible. In the assembled condition of medicament patch 16, however, rigidity in circuit board 68 preferably does not prevent medicament patch 16 from being able to conform to curving skin surfaces at locations on the person of patient at which iontophoretic therapy is to be provided.
  • the embodiment of circuit board 68 shown in Figure 3 B is manufactured from thin sheeting, such as sheeting made from a flexible polyester film, such as Mylar® brand polyester film manufactures by DuPont Teijin Films U.S. Ltd. of Hopewell, Virginia, U.S.A. As a result, circuit board 68 is relatively insubstantial and highly flexible.
  • Intermediate portion 86 of circuit board 68 includes a single layer of circuit board material.
  • first end 82 of circuit board 68 includes a primary layer 92 above a substantially congruent secondary layer 94.
  • Primary layer 92 of first end 82 of circuit board 68 carries electronic circuitry 60 and is a coplanar extension of intermediate portion 86.
  • second end 84 of circuit board 68 includes a primary layer 96 above a substantially congruent secondary layer 98.
  • Primary layer 96 of second end 84 of circuit board 68 carries a portion of printed circuit 78 and is also a coplanar extension of intermediate portion 86.
  • Figure 3C is a perspective view of circuit board 68 of Figure 3B.
  • secondary layer 94 of first end 82 of circuit board 68 has been rotated by 90 degrees in a clockwise direction out of the position thereof shown in Figure 3B about a first axis A t located between secondary layer 94 and primary layer 92 of circuit board 68.
  • secondary layer 98 of second end 84 of circuit board 68 has been rotated by 90 degrees in a counter clockwise direction out of the position thereof shown in Figure 3B about a second axis A 2 located between secondary layer 98 and primary layer 96 of circuit board 68.
  • First axis Ai and second axis A 2 are generally parallel to one another and perpendicular to the longitudinal extent of circuit board 68 at the opposite ends thereof. Variations in such relationships would not be contrary to teachings of the present invention, as first axis Ai and second axis A 2 can with substantially equivalent efficacy be intersecting relative to each other, or be individually or jointly located to one side or on opposite sides of the longitudinal extent of a circuit board, such as circuit board 68.
  • circuit board 68 depicted in Figure 3C reveals that at first axis Ai, primary layer 92 and secondary layer 94 of first end 82 of circuit board 68 are connected by a bendable first electrode hinge 100. Similarly, at second axis A 2 , primary layer 96 and secondary layer 98 of second end 84 of circuit board 68 are connected by a bendable second electrode hinge 102.
  • first electrode hinge 100 and second electrode hinge 102 may be structures distinct from the portions of circuit board 68 interconnected thereby.
  • one or both of secondary layer 94 and secondary layer 98 would be manufactured as distinct articles and then interconnected during further manufacturing activities by a corresponding one or both of first electrode hinge 100 and second electrode hinge 102. This could be a desirable arrangement, where the material of circuit board 68 is rigid or only partially flexible.
  • secondary layer 94, secondary layer 98, and the central portion of circuit board 68 between first axis Ai and second axis A 2 could be manufactured from such a rigid or only partially flexible material and subsequently interconnected by flexible or mechanically bendable hinges, such as first electrode hinge 100 and second electrode hinge 102.
  • first electrode hinge 100 and second electrode hinge 102 are coplanar extension of the portions of circuit board 68 interconnected thereby.
  • the required capacity for bending in first electrode hinge 100 and second electrode hinge 102 arises from the flexibility of the material of which circuit board 68 is manufactured. Were that material rigid or only partially flexible, the degree of bendability required in first electrode hinge 100 and second electrode hinge 102 can be achieved without departing from teachings of the present invention by thinning or scoring the side of each of first electrode hinge 100 and second electrode hinge 102 that is not visible in Figure 3C.
  • support face 76 of circuit board 68 extends in a continuous manner across first electrode hinge 100 to secondary layer 94 of first end 82 and across second electrode hinge 102 to secondary layer 98 of second end 84.
  • Active electrode 50 can be appreciated from Figure 3 C to be carried on a portion of support face 76 that extends onto secondary layer 98 of second end 84 of circuit board 68 and to be electrically coupled to other electrical circuit elements of medicament patch 16 by the portion of printed circuit 78 that traverses second electrode hinge 102.
  • circuit board 68 opposite from support face 76 thereof is a continuous surface that may, if convenient, remain entirely free of electrical circuit elements.
  • a portion of such a continuous attachment face 104 of circuit board 68 is visible on the side of secondary layer 94 of first end 82 of circuit board 68 presented in Figure 3C.
  • attachment face 104 on secondary layer 94 of first end 82 of circuit board 68 engages attachment face 104 on primary layer 92 of first end 82
  • attachment face 104 on secondary layer 98 of second end 84 engages attachment face 104 on primary layer 96 of second end 84.
  • Figure 3D is a perspective view of circuit board 68 of Figure 3C.
  • secondary layer 94 of first end 82 of circuit board 68 has been rotated by an additional 90 degrees in a clockwise direction out of the position thereof shown in Figure 3C about first axis Ai.
  • secondary layer 98 of second end 84 of circuit board 68 has been rotated by an additional 90 degrees in a counter clockwise direction out of the position thereof shown in Figure 3C about a second axis A 2 .
  • depicted in Figure 3D is the fully unfolded, planar state of circuit board 68.
  • an active transdermal medicament patch employing a circuit board having mounted on an attachment face thereof a power source and an electrode, such as return electrode 42 or active electrode 50, is provided with electrode flexion means that traverses the circuit board intermediate the electrode and the power source for permitting bending of the circuit board between a planar state of the circuit board and a compact state of the circuit board.
  • electrode flexion means that traverses the circuit board intermediate the electrode and the power source for permitting bending of the circuit board between a planar state of the circuit board and a compact state of the circuit board.
  • a portion of the attachment face in an electrode region of the circuit board located on the same side of the electrode flexion means as the electrode engages a portion of the attachment face in a power source region of the circuit . board located on the same side of the electrode flexion means as the power source.
  • an active transdermal medicament patch to benefit from the use of a circuit board that is in effect electrically two-sided, but that carries only on a single side thereof the electrical circuit components of the medicament patch. This leaves the other side of the circuit board free of electrical circuit components.
  • the freedom to maintain one side of the circuit board free of electrical circuit components is an optional benefit of an electrode flexion means incorporating teachings of the present invention.
  • circuit board 68 includes a first electrode region corresponding to secondary layer 94 of first end 82 and a power source region corresponding to the portion of circuit board 68 on the same side of first axis Ai as power source 62.
  • First electrode hinge 100 traverses circuit board 68 between return electrode 42 and power source 62 and permits circuit board 68 to bend out of the planar state thereof shown in Figure 3D and into a more compact state thereof shown in Figure 3B.
  • attachment face 104 on secondary layer 94 of first end 82 of circuit board 68 engages attachment face 104 on primary layer 92.
  • circuit board 68 includes a second electrode region corresponding to secondary layer 98 of second end 84 and a power source region corresponding to the portion of circuit board 68 on the same side of second axis A 2 as power source 62.
  • Second electrode hinge 102 traverses circuit board 68 between active electrode 50 and power source 62 and permits circuit board 68 to bend out of the planar state thereof shown in Figure 3D and into a more compact state thereof shown in Figure 3B.
  • attachment face 104 on secondary layer 98 of first end 84 of circuit board 68 engages attachment face 104 on primary layer 96.
  • return electrode 42 is depicted above and separated from support face 76 of circuit board 68. Revealed thereby is a return electrode contact pad 106 in which printed circuit 78 terminates on secondary layer 94 of first end 82 of circuit board 68. Superimposed by way of reference in phantom on support face 76 is periphery 44 of return electrode 42, which in the assembled condition of medicament patch 16 shown in Figure 2B entirely obscures return electrode contact pad 106.
  • Active electrode 50 is depicted in Figure 3D above and separated from support, face 76 of circuit board 68. Revealed thereby is an active electrode contact pad 108 in which printed circuit 78 terminates on secondary layer 98 of second end 84 of circuit ' board 68. Superimposed by way of reference in phantom on support face 76 is periphery 106 of backing layer 52 of active electrode 50, which in the assembled condition of medicament patch 16 shown in Figure 2B entirely obscures active electrode contact pad 108.
  • Figure 4 is a cross-sectional elevation view of medicament patch 16 taken along section line 4-4 in Figure 2A.
  • Figure 4 depicts in edge view both sides of substrate 18, as well as the interaction by way of first electrode aperture 40 and second electrode aperture 48 of other elements of medicament patch 16 discussed previously.
  • circuit board 68 is shown in the fully folded, compact state thereof carrying electrical circuit components. From among the electrical circuit components carried on circuit board 68, printed circuit 78 been omitted out of convenience due to the thinness thereof. Nonetheless, the entirety of printed circuit 78 is disposed as shown in Figure 3D, on support face 76 along with the balance of the electrical circuit elements of medicament patch 16.
  • release liner 22 is in the process of being peeled from therapeutic face 20 of substrate 18, thereby to free the adhesive coating on therapeutic face 20 for the releasable attachment of medicament patch 16 to the skin of a patient. Simultaneously, the detachment of release liner 22 from medicament patch 16 will result in the removal of stray droplets of medicament solution 36.
  • Securement surface 74 of medicament matrix 30 engages pH-control layer 54 and backing layer 52 of active electrode 50 interior of second electrode aperture 48.
  • attachment face 104 of secondary layer 98 engages attachment face 104 of primary layer 96.
  • Electronic circuitry 60, power source 62, and switch 64 are carried on support face 76 of circuit board 68 and sealed therewith against upper face 70 of substrate 18 by cover 56.
  • attachment face 104 of secondary layer 94 engages attachment face 104 of primary layer 92 interior of first . electrode aperture 40.
  • Figures 5A and 5B are related diagrams that compare the movement of medicaments of differing polarities through the skin of a wearer of medicament patch 16.
  • the alterations in electrical interconnections required among element of medicament patch 16 to produce those movements are not illustrated, but will be mentioned.
  • Figure 5 A illustrates the movement of molecules of a positive medicament M + that exhibits a net positive polarity.
  • Therapeutic face 20 of substrate 18 is shown as being disposed against the surface 110 of skin 112. Then skin contact surface 34 of medicament matrix 30 and skin contact surface 46 of return electrode 42 each electrically conductively engage surface 1 10 of skin 1 12 at separated locations. Aside from the conductivity of skin 1 12, these locations are electrically isolated from each other.
  • the negative pole of power source 34 is coupled directly or indirectly to return electrode 42.
  • the positive pole of power source 62 is coupled directly or indirectly to medicament matrix 30, which engages skin 112 at a location remote from return electrode 42.
  • an electrical skin current Is is schematically indicated by a solid arrow to flow through skin 112 from medicament matrix 30, which is associated with the positive pole of power source 62, to return electrode 42 associated with the negative pole of power source 62.
  • medicament patch 16 to administer a positive medicament M + , the direction of movement of molecules of positive medicament M + through skin 1 12 thus coincides with the direction of skin current I 5 .
  • Skin resistance Rs varies among human subjects over a wide range. Generally, within a few minutes of beginning to conduct a skin current, such as skin current Is, the skin resistance Rs of most subjects undergoes transient changes and stabilizes at about 10 kilo-ohms, or more broadly stabilizes in a range of from about 10 kilo-ohms to about 50 kilo-ohms.
  • the transcutaneous administration is depicted of molecules of a negative medicament M ' that exhibits a net negative polarity.
  • Therapeutic face 20 of substrate 18 is shown again as being disposed against surface 110 of skin 112.
  • skin contact surface 34 of medicament matrix 30 and skin contact surface 46 of return electrode 42 each electrically conductively engage surface 1 10 of skin 1 12 at separated locations. Aside from the conductivity of skin 112, these locations are electrically isolated from each other.
  • the presence of electrical resistance in skin 112 is indicated schematically in Figure 5B as skin resistance Rs.
  • the electrical components of a medicament patch incorporating teachings of the present invention must be altered from those described above relative to Figure 5 A.
  • the positive pole of power source 62 is coupled directly or indirectly to return electrode 42.
  • the negative pole of power source 62 is coupled directly or indirectly to medicament matrix 30.
  • the electromotive differential thusly applied to skin 112 between return electrode 42 and medicament matrix 30 induces molecules of negative medicament M " to move as negative ions out of medicament matrix 30 toward skin 1 12, across the unbroken surface 110 of skin 112, and through skin 112 in the direction of return electrode 42. This movement is indicated in Figure 5B by a dashed arrow labeled M " .
  • the flow of electrical current in an electrical circuit is conventionally indicated as a flow through the circuit from the positive to the negative pole of the power source employed therewith.
  • a skin current Is schematically indicated by a solid arrow to flow through skin 1 12 toward medicament matrix 30, which is associated with the negative pole of power source 62, from return electrode 42 associated with the positive pole of power source 62.
  • the movement of molecules of negative medicament M " through skin 112 is in a direction that is opposite to that of skin current Is.
  • an active transdermal medicament patch such as medicament patch 16 in Figures 1 -5B, includes voltage means non-removably carried on the substrate of the medicament patch that is driven by a power source that is also carried on that substrate.
  • the voltage means performs a pair of functions. First, the voltage means is for generating a substantially invariant voltage output during a predetermined therapy period. Second, the voltage means is for applying that substantially invariant voltage output across a medicament matrix carried on the substrate of the medicament patch and skin of a patient that is engaged by the medicament matrix.
  • the inventive voltage means performs these functions, notwithstanding the variability inherent in the output potential of a portable power source, such as power source 62. Such a power source will exhibit a precipitous decline in output of at least 5% upon being first activated. Thereafter, the output of such a power source will decline relatively steadily in output by about 5% or more during each succeeding hour of operation.
  • an active transdermal medicament patch such as medicament patch 16 in Figures 1 -5B
  • a voltage means of the type described causes a substantially constant skin current Is to flow through the medicament matrix of the medicament patch and skin of a wearer of the medicament patch during the entire course of the predetermined therapy period.
  • the total dosage D T of medicament delivered by an active transdermal medicament patch incorporating teachings of the present invention is deterfninable with reasonable medical reliability by reference to the total of the time during which the medicament patch is employed for therapy.
  • certain electrical components of the types called for in the exemplary embodiment of an inventive circuit disclosed herein as being suitable to performing the functions of an inventive voltage means are occasionally susceptible, due to heating or otherwise, of mildly transient start-up performances. These also stabilize after a relatively short fraction of any normal therapy period and produce no more than a negligible effect on the overall dose of medicament ultimately administered during that entire therapy period.
  • any such biological or electrical transients as might be observable in commencing the administration of medicament using apparatus and methods of the present invention do not derogate from what is medically accepted to be a substantially constant flow of skin current through the medicament matrix of an associated medicament patch and the skin of a wearer of the medicament patch during the entire course of some predetermined therapy period.
  • Electronic circuitry 60 includes a voltage regulator 120, which is coupled directly to the positive pole P + of power source 62.
  • Power source 62 supplies a voltage that drives voltage regulator 120 and the other elements of electronic circuitry 60.
  • the output of voltage regulator 120 is supplied to return electrode 42, which engages skin 1 12 of a patient. Together with power source 62, voltage regulator 120 causes an electrical skin current Is to flow through skin 112 from return electrode 42 in the direction shown, overcoming in the process electrical skin resistance Rs of skin 112.
  • the negative pole P " of power source 62 is coupled through switch 64 and active electrode 50 to medicament matrix 30, which engages skin 112 of a patient at a location that is remote from return electrode 42.
  • medicament matrix 30 is filled with molecules of a negative medicament M " .
  • a flow of molecules of negative medicament M " is induced from medicament matrix 30, through skin 112, and toward return electrode 42 in a direction that is opposite to that of skin current Is-
  • Voltage regulator 120 includes a programmable microprocessor 122 having contact pins P1-P8.
  • Microprocessor 122 is a semiconductor chip that includes a read- only memory that retains data when power to microprocessor 122 is terminated, but that can be electronically erased and reprogrammed without being removed from the circuit board upon which microprocessor 122 is mounted with other electrical circuit components.
  • microprocessor 122 exhibits low power consumption requirements, which are in harmony with the use of a small, non-rechargeable mobile power source, such as power source 62.
  • microprocessor 122 Software installed in microprocessor 122 enables various of contact pins P1-P8 to performing multiple functions.
  • the physical size of microprocessor 122 is accordingly small as compared with a microprocessor carrying only single-use contact pins, and the physical coupling of microprocessor 122 with other electrical circuit elements of electronic circuitry 60 necessitates fewer lead attachment soldering operations than would be the case using single-use contact pins. This reduces manufacturing costs and failures, as well as contributes to a desirably small footprint in microprocessor 122.
  • contact pin P6 and contact pin P7 of microprocessor 122 are not used.
  • Positive pole P + of power source 62 is coupled directly to contact pin Pl, which therefore functions as an input contact for microprocessor 122.
  • Contact pin P8 is • grounded.
  • the voltage output from voltage regulator 120 appears at contact pin P5 of microprocessor 122. Therefore, contact pin P5 functions as an output contact for microprocessor 12, and contact pin P5 is coupled directly to return electrode 42.
  • a sensing resistor 124 is electrically coupled between contact pin P5 and contact pin P2, which therefore functions as a current monitoring contact for microprocessor 122.
  • an active transdermal medicament patch such as medicament patch 16 in Figures 1-5B, includes activity indication means non-removably carried on the substrate of the medicament patch for communicating to a user that a voltage means as described above is operating.
  • electronic circuitry 60 includes an indicator circuit 130.
  • Indicator circuit 130 includes light-emitting diode 67 and a bias resistor 132 that are series-connected between contact pin Pl of microprocessor 122 and contact pin P3, which therefore functions as an activity indication contact for microprocessor 122.
  • Microprocessor 122 necessarily includes a driver that operates light-emitting diode 67 in any selected manner preferred by medical personal and suited to the sensory capacities of the patient with whom medicament patch 16 is to be used for therapy.
  • a driver in microprocessor 122 might be programmed to operate light- emitting diode 67 only on an intermittent basis during any therapy period in order to conserve the capacity of power source 62 for use by other electrical elements of electronic circuitry 60.
  • indicator circuit 130 could employ in place of light-emitting diode 67 an auditory indicator or a tactile indicator that engages skin 112 of the patient or that can be encountered at will by attending medical personnel in the manner of taking a pulse.
  • a tactile indicator could, for example, be a vibrating element or a heating element.
  • Auditory or tactile indicators may consume the output capacity of power source 62 more rapidly than a light- emitting diode, and particularly more rapidly than an intermittently-operated light- emitting diode.
  • the migration of medicament through skin 112 is reflected as a flow of skin current Is from contact pin P5 of microprocessor 122 to return electrode 42.
  • the flow of skin current Is is detected at contact pin P2 of microprocessor 122, whereby microprocessor 122 is able, by integrating the flow of skin current Is over time, to monitor the running cumulative total of the amount of medicament administered.
  • microprocessor 122 is programmed to function as a circuit breaker and disable power source 62, thereby terminating skin current Is and the migration of medicament through skin 112.
  • Voltage regulator 120 is so configured as to cause the voltage applied through skin 112 between return electrode 42 and medicament matrix 30 to be substantially invariant for the full duration of a predetermined therapy period T M that ranges in duration from about 1 hour to about 6 hours, or more narrowly from about 2 hours to about 4 hours. Any such substantially invariant voltage applied through skin 112 between return electrode 42 and medicament matrix 30 will cause iontophoretic medicament migration to occur through skin 112 from medicament matrix 30 to return electrode 42 at a substantially constant rate.
  • microprocessor 122 When medicament migration occurs at a substantially constant rate, skin current Is is substantially constant, and the integration function to be performed by microprocessor 122 in monitoring the administration of total dosage Dj of medicament reduces to one of using a clock in microprocessor 122 to time the duration of the period during which the substantially constant skin current Is has been produced. When the output of that timer reaches the ratio of total dosage Dj of medicament divided by the substantially constant skin current Is, microprocessor 122 is programmed to function as a circuit breaker and disable power source 62, thereby terminating skin current Is and the migration of additional medicament through skin 1 12.
  • R 1 100 kilo-ohm resistor ERJ-6 GEYJ 104 V of the type manufactured by Panasonic Corporation of North America of Secaucus, New Jersey U.S.A.;
  • R 2 300 ohm printed resistor
  • the enlarged-scale version of the voltage performance curve, therapy period T M is for convenience of analysis divided into a plurality of four (4) equal therapy subsessions Si, S 2 , S 3 , and S 4 of 70 minutes each.
  • power source 62 is activated by a user through the operation of switch 64.
  • voltage V 3.18 volts, greater even than the nominal 3.00 volt rating of power source 62 when configured as a battery B of the type specified in the above list of electrical circuit component in Figure 6.
  • voltage V declines steeply in a seemingly linear manner.
  • voltage V 3.00 volts.
  • voltage V commences a relatively sharp decline in slope, decaying asymptotically toward the horizontal.
  • Figures 8A and 8B are the same performance curve, but drawn in contrasting respective scales to depict the skin current Is produced by voltage V depicted in Figures 7A and 7B.
  • the enlarged-scale version of the skin current performance curve, therapy period T M has for consistency of analysis been divided into the same plurality of therapy subsessions Si, S 2 , S 3 , and S 4 as appeared in Figure 7B.
  • the initial transient behavior of voltage V is closely reflected in skin current Is-
  • skin current Is 0.318 milliamperes.
  • skin current Is declines steeply in a seemingly linear manner.
  • skin current Is 0.300 milliamperes.
  • skin current Is commences a relatively sharp decline in slope, decaying asymptotically toward the horizontal.
  • that initial transient behavior of skin current Is has a negligible effect on the total dosage Dj of medicament administered.
  • the total dosage Oy of medicament administered has been divided into a plurality of four (4) medicament subdoses Di, D 2 , D 3 , and D 4 , which correspond in a one-to-one manner to the amount of medicament administered during each of therapy subsessions Si, S 2 , S 3 , and S 4 , respectively.
  • therapy subdose Di represents the amount of medicament administered in therapy subsession Si
  • therapy subdose D 2 represents the amount of medicament administered in therapy subsession S 2 ; and so forth.
  • the performance curve of Figure 9 is thus derived directly from Figures 8 A-8B, being a plot of the value of the area beneath the performance curve of skin current Is in those drawings.
  • cumulative dosage D is substantially strictly linear, reflecting the administration in each of therapy subsessions Sj, S 2 , S 3 , and S 4 of corresponding equal medicament subdoses Di, D 2 , D 3 , and D 4 of about 40 milliampere-minutes.
  • an active medicament patch such as medicament patch 16
  • dosage control means carried non- removably on the substrate of the medicament patch for limiting to a predetermined medicament quantity the total medicament migrated iontophoretically from the medicament matrix into the skin of the patient during, what under the circumstances becomes, a plurality of temporally non-contiguous therapy subsessions.
  • the portion of therapy period T M preceding any interruption thereof and the balance of therapy period T M that must of necessity be undertaken following such an interruption are examples of a pair of such temporally non-contiguous therapy subsessions.
  • a dosage control means incorporating teachings of the present invention be able to accommodate for any number of interruptions in therapy during any single intended therapy period T M .
  • Such a situation might arise, for example, were it desirable under circumstances like those depicted in the performance curves of Figures 7A-9 to interrupt therapy for a brief respite at the end of several or each of therapy subsessions Si, S 2 , and S 3 .
  • Such an interruption or interruptions might be needed in order to inspect the skin of the patient at the site of therapy or to adjust the positioning of medicament patch 16 on the skin of the patient.
  • a dosage control means includes a medicament migration detector that includes microprocessor 122 and sensing resistor 124 electrically coupled as shown to power source 62, return electrode 42, and medicament matrix 30.
  • a dosage control means need not necessarily be contained within or associated with circuitry that, like voltage regulator 120, is capable of imposing a substantially invariant voltage V between return electrode 42 and medicament matrix 30.
  • the medicament migration detector continuously monitors the flow of skin current Is and, thereby, the iontophoretic migration of medicament from medicament matrix 30 into the skin of the patient. As an output, the medicament migration detector produces a continuous measure of the instantaneous rate of that iontophoretic medicament migration.
  • a dosage control means in combination with such a medicament migration detector, includes a dosage integrator that operates on the output of the medicament migration detector to produce as an output a running cumulative total of the amount of medicament delivered by iontophoretic migration.
  • a dosage control means may, for example, be effected in the software in microprocessor 122, or in the alternative may be embodied in software or hardware located elsewhere than within microprocessor 122.
  • a circuit breaker disables power source 62, when the output of the dosage integrator equals the predetermined total dosage D T associated with the full predetermined therapy period T M .
  • Such a circuit breaker may, for example, be effected in the software in microprocessor 122, or in the alternative may be embodied in software or hardware located elsewhere than within microprocessor 122. In this manner, following any interruption in the administration of medication, the dosage control means resumes monitoring the amount of medication administered where that administration was at the time of the interruption.
  • Power source 62 may be so electrically coupled between return electrode 42 and medicament matrix 30 as to cause iontophoretic medicament migration from medicament matrix 30 into the skin of the patient to occur at a substantially constant rate. Such would be the case where the capability of a voltage regulator, such as voltage regulator 120, is included among associated electrical circuit components. Under such circumstances, a dosage control means incorporating teachings of the present invention includes, a medicament migration detector as described above and a timer active only when the output of the medicament migration detector exceeds a predetermined minimum rate of medicament migration associated with a closed circuit. Such a timer may, for example, be effected in the software in microprocessor 122, or in the alternative may be embodied in software or hardware located elsewhere than within microprocessor 122. A circuit breaker disables power source 62, when the duration of the activity of the timer equals the ratio of the predetermined total dose D T of medicament divided by the substantially constant rate of iontophoretic medicament migration being produced
  • an active medicament patch such as medicament patch 16 includes therapy status advisement means that is non-removably carried on the substrate of that medicament patch, and that is driven by a power source, such as power source 62.
  • the therapy status advisement means performs the function of communicating to a user the extent of completion of predetermined therapy period T M during which a medicament is to be iontophoretically delivered from medicament matrix 30 into the skin of a patient.
  • a therapy status advisement means incorporating teachings of the present invention includes microprocessor 122, light-emitting diode 67, and bias resistor 132 as shown electrically coupled to power source 62, return electrode 42, and medicament matrix 30.
  • the therapy status advisement means may employ an auditory indicator or a tactile indicator of the type described earlier.
  • the therapy status advisement means need not necessarily be contained within or associated with circuitry that, like voltage regulator 120, is capable of imposing a substantially invariant voltage V between return electrode 42 and medicament matrix 30.
  • a therapy status advisement means configured according to teachings of the present invention is a timer that is active only during therapy period T M and a driver for light-emitting diode 67 that causes light-emitting diode 67 to operate only when the timer is active.
  • a driver for light-emitting diode 67 that causes light-emitting diode 67 to operate only when the timer is active.
  • light-emitting diode 67 is operated intermittently to minimize power consumption.
  • Such a timer and such a driver may, for example, be effected in the software in microprocessor 122, or in the alternative may be embodied in software or hardware located elsewhere than within microprocessor 122.
  • Therapy period T M may include a sequence of non-overlapping predetermined therapy subsessions, such as therapy subsessions Si, S 2 , S 3 , and S 4 of therapy period T M depicted in the performance curves of Figures 7B, 8B, and 9.
  • Therapy period T M may include more or fewer therapy subsessions, and those therapy subsessions need not be of substantially equal duration, as in the case of therapy subsessions Si, S 2 , S 3 , and S 4 .
  • the driver of the therapy status advisement means may then activate light-emitting diode 67, or any auditory or tactile indicator used in place thereof, in a distinct mode of operation during each of the therapy subsessions, respectively.
  • the driver of the therapy status advisement means may cause light-emitting diode 67 or any auditory or tactile indicator used in place thereof, to operate in a contrasting transition mode at the end of a selected one or a selected plurality of the therapy subsessions, including at the end of final therapy subsession S 4 at the termination of therapy period T M -
  • the driver of the therapy status advisement means may cause light-emitting diode 67 or any auditory or tactile indicator used in place thereof, to operate in a contrasting alarm mode when the timer of the therapy status advisement means is deactivated prior to the termination of therapy period T M - Such would be the case where therapy during a full predetermined therapy period T M is interrupted due to the temporary removal of medicament patch 16 from the skin of the patient.
  • therapy status advisement means is thus governed by the driver of therapy status advisement means, which activates light-emitting diode 67, or any auditory or tactile indicator used in place thereof, in a discrete variety of operative modes P, each of which is reflective of a foreseeable medicament administration status condition X.
  • Each status condition X thus includes temporal and electrical information, information relative to the time T within therapy period T M and information relative to the existence or nonexistence of skin current Is in the skin of the patient.
  • status condition X can denote that therapy is in a specific one of a plurality of therapy subsessions, such as therapy subsessions Si, S 2 , S 3 , and S 4 , or that therapy is at the end of a chosen one or of all of those therapy subsessions. Electrically, status condition X denotes whether skin current Is is flowing, or whether skin current Is is zero by being less than some predetermined minimum amount chosen to evidence an open circuit. The later would be the case, for example, were the resistance between medicament matrix 30 and return electrode 42 to be detectable as exceeding an arbitrary upper threshold, such as 500 kilo-ohms, which is beyond the range of the likely skin resistance Rs in any patient.
  • an arbitrary upper threshold such as 500 kilo-ohms
  • the operative mode P of light-emitting diode 67 is a function of status condition X.
  • a table listing typical status conditions X and an exemplary operative mode P(X) corresponding to each for a therapy period T M that is comprised of a non-overlapping sequence of therapy subsessions Si, S 2 , S 3 , and S 4 .
  • Distinct first and second operative transition modes are produced in light-emitting diode 67 half way through therapy period T M at the end of therapy subsession S 2 , and at the completion of therapy period T M when therapy subsession S 4 ends.
  • T TM and S 2 has ended Continuous LED-flashes of duration Ai at (second transition mode) regular intervals of duration E 3 for an extended period of duration K 2
  • the depicted methodology commences at initiation oval 140 by turning voltage V on as required in procedure rectangle 142. This occurs when power source 62 is activated by a user through the operation of switch 64. Thereupon, if medicament patch 16 is in place on skin 1 12 of a patient, voltage regulator 120 should begin to apply voltage V across skin 112 between medicament matrix 30 and return electrode 42, and skin current Is should begin to flow.
  • microprocessor 122 undertakes the inquiry in decision diamond 144 to determine whether skin current Is has commenced. If not, microprocessor 122 continues repeatedly to operate in a functional loop 150 that includes decision diamond 144, procedure rectangle 146, and procedure rectangle 148.
  • microprocessor 122 idles for a predetermined period Wait 2 and then undertakes the inquiry in decision diamond 162 to determine whether a closed circuit continues to exist in which a flow of skin current Is is occurring. If it is determined that skin current Is continues to be flowing, activity returns to decision diamond 156 and continues repeatedly through a functional loop 164 that includes decision diamond 156, procedure rectangle 158, procedure rectangle 160, and decision diamond 162.
  • therapy is understood to be starting the next successive therapy subsession S N+ i, or in other words to be starting therapy subsession S 2 , which follows therapy subsession Si.
  • Procedure rectangle 176 and decision diamond 178 thus make up a functional branch 180 by which microprocessor 122 resisters that therapy has advanced into a successive therapy subsession.
  • the driver of light-emitting diode 67 in microprocessor 122 operates light-emitting diode 67 in operative mode P(S 2 ) to advise the user that medicament patch 16 is operational and that therapy is progressing in therapy subsession S 2 .
  • operative mode P(X) the driver of light-emitting diode 67 in microprocessor 122 operates light-emitting diode 67 in operative mode P(S 2 ) to advise the user that medicament patch 16 is operational and that therapy is progressing in therapy subsession S 2 .
  • operative mode P(X) light-emitting diode 67 is made to flash twice for 0.25 seconds at regular intervals of 0.50 seconds.
  • the illustrated methodology continues in functional loop 164, until the inquiry undertaken by microprocessor 122 in decision diamond 156 reveals that therapy subsession S 2 has been completed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un timbre transdermique de médicament actif (16), qui comprend un substrat planaire (18) avec une face thérapeutique (20) pouvant être maintenue de façon libérale contre la peau (112) d'un patient (10). Une électrode de référence (42) et une matrice de médicament (30) sensible à la perméation d'un médicament (M+, M-) sont fixées à des emplacements séparés sur la face thérapeutique (20). Chacune entre en contact électrique et conducteur avec la peau (112), lorsque le substrat (18) est retenu sur celle-ci. Une source d'alimentation (62) portée par le substrat (18) est électriquement couplée entre la matrice de médicament (30) et un microprocesseur programmé (122) également porté par le substrat (18). Une tension sensiblement invariante présentée au niveau d'un contact de sortie (P4) du microprocesseur (122) est appliquée pendant une période thérapeutique prédéterminée (TM) à travers la peau (112) entre la matrice de médicament (30) et l'électrode de référence (42), ce qui induit une migration transcutanée de médicament (M+, M-) dans la peau (112) à un taux sensiblement constant. Une diode électroluminescente (67) portée sur le substrat (18) et couplée au microprocesseur (122) communique que le timbre (16) est opérationnel.
PCT/US2008/009452 2008-01-18 2008-08-06 Timbre transdermique de médicament actif WO2009091372A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/009,409 US20080214985A1 (en) 2007-02-02 2008-01-18 Active transdermal medicament patch
US12/009,443 2008-01-18
US12/009,443 US8862223B2 (en) 2008-01-18 2008-01-18 Active transdermal medicament patch and circuit board for same
US12/009,409 2008-01-18

Publications (1)

Publication Number Publication Date
WO2009091372A1 true WO2009091372A1 (fr) 2009-07-23

Family

ID=40885557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009452 WO2009091372A1 (fr) 2008-01-18 2008-08-06 Timbre transdermique de médicament actif

Country Status (1)

Country Link
WO (1) WO2009091372A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US5667487A (en) * 1993-04-07 1997-09-16 Henley; Julian L. Ionosonic drug delivery apparatus
US5843014A (en) * 1995-03-24 1998-12-01 Alza Corporation Display for an electrotransport delivery device
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
US20070093788A1 (en) * 2005-09-30 2007-04-26 Darrick Carter Iontophoresis method and apparatus for systemic delivery of active agents
US20080004564A1 (en) * 2006-03-30 2008-01-03 Transcutaneous Technologies Inc. Controlled release membrane and methods of use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708716A (en) * 1983-08-18 1987-11-24 Drug Delivery Systems Inc. Transdermal drug applicator
US5667487A (en) * 1993-04-07 1997-09-16 Henley; Julian L. Ionosonic drug delivery apparatus
US5843014A (en) * 1995-03-24 1998-12-01 Alza Corporation Display for an electrotransport delivery device
US6745071B1 (en) * 2003-02-21 2004-06-01 Birch Point Medical, Inc. Iontophoretic drug delivery system
US20070093788A1 (en) * 2005-09-30 2007-04-26 Darrick Carter Iontophoresis method and apparatus for systemic delivery of active agents
US20080004564A1 (en) * 2006-03-30 2008-01-03 Transcutaneous Technologies Inc. Controlled release membrane and methods of use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same

Similar Documents

Publication Publication Date Title
US9956403B2 (en) Active transdermal medicament patch and circuit board for same
US20080214985A1 (en) Active transdermal medicament patch
US11944809B2 (en) Systems and methods for treating shoulder pain related to subacromial impingement syndrome
US20110160640A1 (en) Operation management of active transdermal medicament patch
US20080188791A1 (en) Active iontophoresis delivery system
US6792306B2 (en) Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor
EP2563456B1 (fr) Systèmes et procédés pour une stimulation électrique percutanée
US8197844B2 (en) Active electrode for transdermal medicament administration
US5876368A (en) Iontophoretic drug delivery device having improved controller
US5795321A (en) Iontophoretic drug delivery system, including removable controller
EP0957977A1 (fr) Systeme d'apport d'un medicament iontophoretique comrenant un timbre adhesif jetable
NZ305165A (en) Display for electrotransport delivery and method for operating display
WO1998013100A1 (fr) Systeme d'administration de medicaments par iontophorese, comprenant une unite de distribution de timbres
AU7119096A (en) Iontophoretic drug delivery system, including reusable device
WO2009091372A1 (fr) Timbre transdermique de médicament actif
WO1996010441A9 (fr) Systeme d'administration d'un medicament par ionophorese, comprenant un timbre a usage unique et un dispositif de commande amovible, reutilisable
WO1996010441A1 (fr) Systeme d'administration d'un medicament par ionophorese, comprenant un timbre a usage unique et un dispositif de commande amovible, reutilisable
AU2007203591B2 (en) Finger-mounted electrokinetic delivery system for self-administration of medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795079

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795079

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载